25 XP   0   0   10

Indofarma Tbk
Buy, Hold or Sell?

Let's analyse Indofarma together

PenkeI guess you are interested in Indofarma Tbk. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Indofarma Tbk. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Indofarma Tbk

I send you an email if I find something interesting about Indofarma Tbk.

Quick analysis of Indofarma (30 sec.)










What can you expect buying and holding a share of Indofarma? (30 sec.)

How much money do you get?

How much money do you get?
Rp0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
Rp27.86
Expected worth in 1 year
Rp-516.72
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
Rp-544.58
Return On Investment
-418.9%

For what price can you sell your share?

Current Price per Share
Rp130.00
Expected price per share
Rp0 - Rp430.00
How sure are you?
50%

1. Valuation of Indofarma (5 min.)




Live pricePrice per Share (EOD)

Rp130.00

Intrinsic Value Per Share

Rp-275.05 - Rp-76.80

Total Value Per Share

Rp-247.18 - Rp-48.94

2. Growth of Indofarma (5 min.)




Is Indofarma growing?

Current yearPrevious yearGrowGrow %
How rich?$8.6m$50.8m-$42.1m-488.6%

How much money is Indofarma making?

Current yearPrevious yearGrowGrow %
Making money-$42.8m-$3.7m-$39m-91.2%
Net Profit Margin-37.4%-1.3%--

How much money comes from the company's main activities?

3. Financial Health of Indofarma (5 min.)




What can you expect buying and holding a share of Indofarma? (5 min.)

Welcome investor! Indofarma's management wants to use your money to grow the business. In return you get a share of Indofarma.

What can you expect buying and holding a share of Indofarma?

First you should know what it really means to hold a share of Indofarma. And how you can make/lose money.

Speculation

The Price per Share of Indofarma is Rp130.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Indofarma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Indofarma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is Rp27.86. Based on the TTM, the Book Value Change Per Share is Rp-136.15 per quarter. Based on the YOY, the Book Value Change Per Share is Rp25.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is Rp0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Indofarma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 Rp% of Price per ShareRp% of Price per ShareRp% of Price per ShareRp% of Price per ShareRp% of Price per Share
Usd Eps-0.010.0%-0.010.0%0.000.0%0.000.0%0.000.0%
Usd Book Value Change Per Share-0.010.0%-0.010.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%-0.010.0%0.000.0%0.000.0%0.000.0%
Usd Price Per Share0.12-0.12-0.22-0.30-0.26-
Price to Earnings Ratio-8.32--8.32--183.91-90,476.53-45,217.52-
Price-to-Total Gains Ratio-8.45--8.45-88.63--87.75--3.48-
Price to Book Ratio41.27-41.27-13.60-25.96-19.33-
Price-to-Total Gains Ratio-8.45--8.45-88.63--87.75--3.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.013
Number of shares76923
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (76923 shares)-1,047.27-218.44
Gains per Year (76923 shares)-4,189.08-873.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4189-41990-874-884
20-8378-83880-1748-1758
30-12567-125770-2621-2632
40-16756-167660-3495-3506
50-20945-209550-4369-4380
60-25134-251440-5243-5254
70-29324-293330-6116-6128
80-33513-335220-6990-7002
90-37702-377110-7864-7876
100-41891-419000-8738-8750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.05.01.040.0%15.05.03.065.2%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%14.09.00.060.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%1.00.09.010.0%4.00.019.017.4%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%14.09.00.060.9%

Fundamentals of Indofarma

About Indofarma Tbk

PT Indofarma Tbk, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. It offers laboratory, pharmaceutical, and health equipment; orthopedic and prosthetic equipment; industrial machinery for packaging, bottling, and canning; provides health consultancy services; and trades in laboratory equipment, pharmacy, and medicines. The company serves medicine product, medical and dental equipment, electromedical and electrotherapy equipment, herbal processing, and tea processing industries, as well as furniture industry for operations, medical care, and dental care. It also engages in marketing, trading, and distribution of products and related activities. The company was formerly known as PT Indofarma (Persero) Tbk. PT Indofarma Tbk was founded in 1918 and is headquartered in Bekasi, Indonesia. PT Indofarma Tbk is a subsidiary of PT Bio Farma.

Fundamental data was last updated by Penke on 2024-04-22 10:31:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Indofarma Tbk.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Indofarma earns for each Rp1 of revenue.

  • Above 10% is considered healthy but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -37.4% means that Rp-0.37 for each Rp1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Indofarma Tbk:

  • The MRQ is -37.4%. The company is making a huge loss. -2
  • The TTM is -37.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-37.4%TTM-37.4%0.0%
TTM-37.4%YOY-1.3%-36.2%
TTM-37.4%5Y-8.0%-29.4%
5Y-8.0%10Y-4.4%-3.7%
1.1.2. Return on Assets

Shows how efficient Indofarma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • -27.9% Return on Assets means that Indofarma generated Rp-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Indofarma Tbk:

  • The MRQ is -27.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.9%TTM-27.9%0.0%
TTM-27.9%YOY-1.9%-26.1%
TTM-27.9%5Y-6.3%-21.6%
5Y-6.3%10Y-3.5%-2.8%
1.1.3. Return on Equity

Shows how efficient Indofarma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • -496.1% Return on Equity means Indofarma generated Rp-4.96 for each Rp1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Indofarma Tbk:

  • The MRQ is -496.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -496.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-496.1%TTM-496.1%0.0%
TTM-496.1%YOY-7.4%-488.7%
TTM-496.1%5Y-101.7%-394.4%
5Y-101.7%10Y-51.9%-49.8%

1.2. Operating Efficiency of Indofarma Tbk.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Indofarma is operating .

  • Measures how much profit Indofarma makes for each Rp1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated Rp0.00  for each Rp1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Indofarma Tbk:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY1.8%-1.8%
TTM-5Y1.0%-1.0%
5Y1.0%10Y1.1%0.0%
1.2.2. Operating Ratio

Measures how efficient Indofarma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.49 means that the operating costs are Rp2.49 for each Rp1 in net sales.

Let's take a look of the Operating Ratio trends of Indofarma Tbk:

  • The MRQ is 2.488. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.488. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.488TTM2.4880.000
TTM2.488YOY1.808+0.680
TTM2.4885Y1.931+0.557
5Y1.93110Y1.654+0.277

1.3. Liquidity of Indofarma Tbk.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Indofarma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.88 means the company has Rp0.88 in assets for each Rp1 in short-term debts.

Let's take a look of the Current Ratio trends of Indofarma Tbk:

  • The MRQ is 0.877. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.877. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.877TTM0.8770.000
TTM0.877YOY1.350-0.474
TTM0.8775Y1.302-0.426
5Y1.30210Y1.003+0.300
1.3.2. Quick Ratio

Measures if Indofarma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.49 means the company can pay off Rp0.49 for each Rp1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Indofarma Tbk:

  • The MRQ is 0.489. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.489. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.489TTM0.4890.000
TTM0.489YOY0.761-0.272
TTM0.4895Y0.756-0.267
5Y0.75610Y0.698+0.058

1.4. Solvency of Indofarma Tbk.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Indofarma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Indofarma to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.94 means that Indofarma assets are financed with 94.4% credit (debt) and the remaining percentage (100% - 94.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Indofarma Tbk:

  • The MRQ is 0.944. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.944. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.944TTM0.9440.000
TTM0.944YOY0.747+0.196
TTM0.9445Y0.746+0.198
5Y0.74610Y0.665+0.081
1.4.2. Debt to Equity Ratio

Measures if Indofarma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 1,676.3% means that company has Rp16.76 debt for each Rp1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Indofarma Tbk:

  • The MRQ is 16.763. The company is unable to pay all its debts with equity. -1
  • The TTM is 16.763. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ16.763TTM16.7630.000
TTM16.763YOY2.958+13.805
TTM16.7635Y5.270+11.494
5Y5.27010Y3.354+1.915

2. Market Valuation of Indofarma Tbk

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every Rp1 in earnings Indofarma generates.

  • Above 15 is considered overpriced but always compare Indofarma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -8.32 means the investor is paying Rp-8.32 for every Rp1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Indofarma Tbk:

  • The EOD is -0.940. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.318. Based on the earnings, the company is expensive. -2
  • The TTM is -8.318. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.940MRQ-8.318+7.378
MRQ-8.318TTM-8.3180.000
TTM-8.318YOY-183.908+175.589
TTM-8.3185Y90,476.526-90,484.844
5Y90,476.52610Y45,217.518+45,259.008
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Indofarma Tbk:

  • The EOD is -3.196. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -28.276. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -28.276. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.196MRQ-28.276+25.079
MRQ-28.276TTM-28.2760.000
TTM-28.276YOY96.669-124.945
TTM-28.2765Y85.157-113.432
5Y85.15710Y74.962+10.194
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Indofarma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 41.27 means the investor is paying Rp41.27 for each Rp1 in book value.

Let's take a look of the Price to Book Ratio trends of Indofarma Tbk:

  • The EOD is 4.665. Based on the equity, the company is fair priced.
  • The MRQ is 41.271. Based on the equity, the company is expensive. -2
  • The TTM is 41.271. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4.665MRQ41.271-36.606
MRQ41.271TTM41.2710.000
TTM41.271YOY13.597+27.675
TTM41.2715Y25.959+15.312
5Y25.95910Y19.326+6.633
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Indofarma Tbk compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---136.145-136.1450%25.162-641%-28.397-79%-18.190-87%
Book Value Per Share--27.86427.8640%164.010-83%130.778-79%158.238-82%
Current Ratio--0.8770.8770%1.350-35%1.302-33%1.003-13%
Debt To Asset Ratio--0.9440.9440%0.747+26%0.746+26%0.665+42%
Debt To Equity Ratio--16.76316.7630%2.958+467%5.270+218%3.354+400%
Dividend Per Share----0%-0%-0%0.137-100%
Eps---138.246-138.2460%-12.126-91%-31.671-77%-17.640-87%
Free Cash Flow Per Share---40.671-40.6710%23.068-276%-7.792-81%-7.434-82%
Free Cash Flow To Equity Per Share---36.371-36.3710%101.845-136%6.119-694%9.447-485%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.900+11%
Intrinsic Value_10Y_max---76.802--------
Intrinsic Value_10Y_min---275.049--------
Intrinsic Value_1Y_max---3.505--------
Intrinsic Value_1Y_min---12.907--------
Intrinsic Value_3Y_max---13.725--------
Intrinsic Value_3Y_min---51.704--------
Intrinsic Value_5Y_max---27.796--------
Intrinsic Value_5Y_min---104.365--------
Market Cap402905085440.000-785%3564160371200.0003564160371200.0000%6911371850240.000-48%9161441788928.000-61%8069259080396.800-56%
Net Profit Margin---0.374-0.3740%-0.013-97%-0.080-79%-0.044-88%
Operating Margin----0%0.018-100%0.010-100%0.011-100%
Operating Ratio--2.4882.4880%1.808+38%1.931+29%1.654+50%
Pb Ratio4.665-785%41.27141.2710%13.597+204%25.959+59%19.326+114%
Pe Ratio-0.940+89%-8.318-8.3180%-183.908+2111%90476.526-100%45217.518-100%
Price Per Share130.000-785%1150.0001150.0000%2230.000-48%2956.000-61%2603.600-56%
Price To Free Cash Flow Ratio-3.196+89%-28.276-28.2760%96.669-129%85.157-133%74.962-138%
Price To Total Gains Ratio-0.955+89%-8.447-8.4470%88.626-110%-87.753+939%-3.481-59%
Quick Ratio--0.4890.4890%0.761-36%0.756-35%0.698-30%
Return On Assets---0.279-0.2790%-0.019-93%-0.063-77%-0.035-87%
Return On Equity---4.961-4.9610%-0.074-99%-1.017-80%-0.519-90%
Total Gains Per Share---136.145-136.1450%25.162-641%-28.397-79%-18.053-87%
Usd Book Value--8635912.6538635912.6530%50830990.951-83%40531553.989-79%49042101.272-82%
Usd Book Value Change Per Share---0.014-0.0140%0.003-641%-0.003-79%-0.002-87%
Usd Book Value Per Share--0.0030.0030%0.016-83%0.013-79%0.016-82%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.014-0.0140%-0.001-91%-0.003-77%-0.002-87%
Usd Free Cash Flow---12604961.871-12604961.8710%7149533.356-276%-2414986.894-81%-2073658.307-84%
Usd Free Cash Flow Per Share---0.004-0.0040%0.002-276%-0.001-81%-0.001-82%
Usd Free Cash Flow To Equity Per Share---0.004-0.0040%0.010-136%0.001-694%0.001-485%
Usd Market Cap40290508.544-785%356416037.120356416037.1200%691137185.024-48%916144178.893-61%806925908.040-56%
Usd Price Per Share0.013-785%0.1150.1150%0.223-48%0.296-61%0.260-56%
Usd Profit---42846295.424-42846295.4240%-3758063.962-91%-9815819.033-77%-5467075.237-87%
Usd Revenue--114410823.074114410823.0740%290198653.288-61%174276752.179-34%163606912.680-30%
Usd Total Gains Per Share---0.014-0.0140%0.003-641%-0.003-79%-0.002-87%
 EOD+3 -5MRQTTM+0 -0YOY+2 -315Y+4 -2910Y+4 -32

3.2. Fundamental Score

Let's check the fundamental score of Indofarma Tbk based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.940
Price to Book Ratio (EOD)Between0-14.665
Net Profit Margin (MRQ)Greater than0-0.374
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.489
Current Ratio (MRQ)Greater than10.877
Debt to Asset Ratio (MRQ)Less than10.944
Debt to Equity Ratio (MRQ)Less than116.763
Return on Equity (MRQ)Greater than0.15-4.961
Return on Assets (MRQ)Greater than0.05-0.279
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Indofarma Tbk based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than509.254
Ma 20Greater thanMa 50255.450
Ma 50Greater thanMa 100343.860
Ma 100Greater thanMa 200431.060
OpenGreater thanClose132.000
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Net Working Capital  40,255,275348,021,320388,276,595-90,295,713297,980,88268,220,780366,201,662-487,870,550-121,668,889
Gross Profit  259,885,525-7,790,369252,095,156148,504,625400,599,78151,054,204451,653,984-561,762,695-110,108,711
EBITDA  42,857,14811,428,01254,285,16016,046,56270,331,722-109,40670,222,316-531,064,526-460,842,209
Operating Income  25,910,15124,145,07150,055,22250,558,212100,613,4343,565,785104,179,219-583,723,367-479,544,148
Tax Provision  7,438,267-5,654,2641,784,00316,267,57818,051,58128,292,85946,344,440-135,414,630-89,070,190



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in IDR. All numbers in thousands.

Summary
Total Assets1,534,000,447
Total Liabilities1,447,641,320
Total Stockholder Equity86,359,127
 As reported
Total Liabilities 1,447,641,320
Total Stockholder Equity+ 86,359,127
Total Assets = 1,534,000,447

Assets

Total Assets1,534,000,447
Total Current Assets863,577,052
Long-term Assets670,423,394
Total Current Assets
Cash And Cash Equivalents 1,313,787
Short-term Investments 39,000,000
Net Receivables 173,136,177
Inventory 243,968,559
Other Current Assets 59,825,978
Total Current Assets  (as reported)863,577,052
Total Current Assets  (calculated)517,244,501
+/- 346,332,551
Long-term Assets
Property Plant Equipment 462,994,107
Intangible Assets 7,546,198
Other Assets 185,377,661
Long-term Assets  (as reported)670,423,394
Long-term Assets  (calculated)655,917,965
+/- 14,505,429

Liabilities & Shareholders' Equity

Total Current Liabilities985,245,941
Long-term Liabilities462,405,994
Total Stockholder Equity86,359,127
Total Current Liabilities
Short-term Debt 136,465,574
Short Long Term Debt 193,038,119
Accounts payable 525,884,211
Other Current Liabilities 27,677,712
Total Current Liabilities  (as reported)985,245,941
Total Current Liabilities  (calculated)883,065,616
+/- 102,180,325
Long-term Liabilities
Long term Debt Total 431,899,687
Capital Lease Obligations 4,388,978
Long-term Liabilities  (as reported)462,405,994
Long-term Liabilities  (calculated)436,288,665
+/- 26,117,329
Total Stockholder Equity
Common Stock309,926,750
Retained Earnings -615,024,058
Capital Surplus 81,120,061
Other Stockholders Equity 106,992,070
Total Stockholder Equity (as reported)86,359,127
Total Stockholder Equity (calculated)-116,985,177
+/- 203,344,303
Other
Capital Stock309,926,750
Cash And Equivalents268,437,608
Cash and Short Term Investments 269,751,395
Common Stock Shares Outstanding 3,099,268
Liabilities and Stockholders Equity 1,534,000,447
Net Debt 353,072,684
Net Invested Capital 709,183,206
Net Working Capital -121,668,889
Property Plant and Equipment Gross 792,403,403



Balance Sheet

Currency in IDR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
538,173,181
811,624,762
810,027,644
635,959,594
523,923,105
518,823,730
686,937,378
1,009,437,678
965,811,676
728,034,878
733,957,862
1,114,901,670
1,188,618,790
1,294,510,669
1,248,343,275
1,533,708,564
1,381,633,321
1,529,874,782
1,442,350,609
1,383,935,194
1,713,334,659
2,011,879,396
1,534,000,447
1,534,000,4472,011,879,3961,713,334,6591,383,935,1941,442,350,6091,529,874,7821,381,633,3211,533,708,5641,248,343,2751,294,510,6691,188,618,7901,114,901,670733,957,862728,034,878965,811,6761,009,437,678686,937,378518,823,730523,923,105635,959,594810,027,644811,624,762538,173,181
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,068,157,389
853,506,464
930,982,222
867,493,107
829,103,602
1,134,732,820
1,411,390,100
863,577,052
863,577,0521,411,390,1001,134,732,820829,103,602867,493,107930,982,222853,506,4641,068,157,389000000000000000
       Cash And Cash Equivalents 
51,569,750
73,392,650
23,136,705
29,621,430
29,789,272
13,833,462
87,673,073
361,265,503
263,287,772
110,875,234
0
133,417,373
194,902,806
121,432,026
135,754,602
313,472,667
56,233,906
182,587,625
129,324,891
151,387,944
158,178,407
380,814,191
1,313,787
1,313,787380,814,191158,178,407151,387,944129,324,891182,587,62556,233,906313,472,667135,754,602121,432,026194,902,806133,417,3730110,875,234263,287,772361,265,50387,673,07313,833,46229,789,27229,621,43023,136,70573,392,65051,569,750
       Short-term Investments 
51,847,233
51,891,576
40,437,371
28,503,186
40,079,582
21,080,564
11,585,081
3,002,072
9,687,276
750,991
0
28,000
0
0
0
0
0
75,142,120
0
30,000,000
60,000,009
35,000,000
39,000,000
39,000,00035,000,00060,000,00930,000,000075,142,1200000028,0000750,9919,687,2763,002,07211,585,08121,080,56440,079,58228,503,18640,437,37151,891,57651,847,233
       Net Receivables 
159,023,319
222,901,065
212,405,202
130,826,571
105,081,278
147,942,663
241,207,261
250,188,766
213,638,783
307,805,123
278,659,663
340,160,251
390,576,592
471,933,400
410,329,897
431,627,401
476,819,772
229,684,447
299,691,683
294,542,572
559,825,743
379,499,460
173,136,177
173,136,177379,499,460559,825,743294,542,572299,691,683229,684,447476,819,772431,627,401410,329,897471,933,400390,576,592340,160,251278,659,663307,805,123213,638,783250,188,766241,207,261147,942,663105,081,278130,826,571212,405,202222,901,065159,023,319
       Other Current Assets 
11,174,196
59,883,858
85,479,646
111,290,713
84,750,798
73,674,657
93,776,175
78,976,548
149,119,043
19,837,030
23,075,298
39,510,250
30,807,937
19,057,458
20,396,250
12,767,634
16,484,411
251,145,310
206,046,931
212,082,226
227,877,827
281,889,544
59,825,978
59,825,978281,889,544227,877,827212,082,226206,046,931251,145,31016,484,41112,767,63420,396,25019,057,45830,807,93739,510,25023,075,29819,837,030149,119,04378,976,54893,776,17573,674,65784,750,798111,290,71385,479,64659,883,85811,174,196
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
528,126,857
598,892,560
574,857,501
554,831,592
578,601,839
600,489,296
670,423,394
670,423,394600,489,296578,601,839554,831,592574,857,501598,892,560528,126,8570000000000000000
       Property Plant Equipment 
89,186,566
100,585,134
121,980,732
114,509,791
100,403,540
98,434,804
89,495,165
82,009,711
89,228,326
100,990,757
96,937,464
342,984,242
339,196,270
367,912,767
394,584,546
398,427,200
425,706,697
487,333,744
496,765,557
469,100,892
471,236,168
477,146,968
462,994,107
462,994,107477,146,968471,236,168469,100,892496,765,557487,333,744425,706,697398,427,200394,584,546367,912,767339,196,270342,984,24296,937,464100,990,75789,228,32682,009,71189,495,16598,434,804100,403,540114,509,791121,980,732100,585,13489,186,566
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
511,728
585,736
583,636
6,477,896
0
0
0
0
00006,477,896583,636585,736511,728000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
844,908
670,099
16,940,134
14,386,479
13,637,917
13,006,433
39,355,450
37,862,803
3,085,932
16,950,594
17,063,010
11,714,578
7,546,198
7,546,19811,714,57817,063,01016,950,5943,085,93237,862,80339,355,45013,006,43313,637,91714,386,47916,940,134670,099844,9080000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,758,483
7,091,840
7,025,142
2,338,177
150,000
2,108,025
7,145,095
7,145,0952,108,025150,0002,338,1777,025,1427,091,8407,758,4830000000000000000
> Total Liabilities 
245,605,893
294,189,572
412,038,740
368,015,244
268,257,971
253,578,089
406,451,034
717,874,312
669,216,334
429,313,362
422,689,679
505,707,835
538,516,613
703,717,301
656,380,083
940,999,675
805,876,240
1,003,464,885
945,703,749
878,999,867
1,283,008,182
1,503,569,487
1,447,641,320
1,447,641,3201,503,569,4871,283,008,182878,999,867945,703,7491,003,464,885805,876,240940,999,675656,380,083703,717,301538,516,613505,707,835422,689,679429,313,362669,216,334717,874,312406,451,034253,578,089268,257,971368,015,244412,038,740294,189,572245,605,893
   > Total Current Liabilities 
245,605,893
289,757,808
373,223,536
343,160,040
240,875,051
230,322,739
379,341,521
686,297,192
634,575,747
376,911,513
375,535,696
459,403,522
369,863,737
670,902,757
600,565,585
846,731,128
704,929,716
893,289,027
827,237,833
440,827,007
836,751,938
1,045,188,438
985,245,941
985,245,9411,045,188,438836,751,938440,827,007827,237,833893,289,027704,929,716846,731,128600,565,585670,902,757369,863,737459,403,522375,535,696376,911,513634,575,747686,297,192379,341,521230,322,739240,875,051343,160,040373,223,536289,757,808245,605,893
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,527,200
376,738,131
449,818,006
507,583,619
118,622,038
91,858,005
125,089,853
136,465,574
136,465,574125,089,85391,858,005118,622,038507,583,619449,818,006376,738,13111,527,200000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,527,200
376,738,131
449,818,006
507,583,619
118,622,038
91,858,005
203,089,853
193,038,119
193,038,119203,089,85391,858,005118,622,038507,583,619449,818,006376,738,13111,527,200000000000000000
       Accounts payable 
65,671,465
77,664,979
171,314,680
100,599,860
152,640,588
171,119,206
309,975,877
395,344,769
278,092,339
213,445,709
232,162,707
289,874,104
247,767,443
304,641,012
334,684,119
545,995,394
284,808,368
385,141,810
213,561,803
229,722,202
602,640,634
568,662,774
525,884,211
525,884,211568,662,774602,640,634229,722,202213,561,803385,141,810284,808,368545,995,394334,684,119304,641,012247,767,443289,874,104232,162,707213,445,709278,092,339395,344,769309,975,877171,119,206152,640,588100,599,860171,314,68077,664,97965,671,465
       Other Current Liabilities 
77,789,732
80,553,050
41,407,610
102,341,590
72,734,463
37,727,282
69,365,644
111,105,065
78,752,211
75,928,727
54,245,776
88,730,352
45,886,407
47,690,558
42,028,594
15,424,109
13,725,570
7,255,925
23,542,053
8,525,552
33,653,524
107,596,324
27,677,712
27,677,712107,596,32433,653,5248,525,55223,542,0537,255,92513,725,57015,424,10942,028,59447,690,55845,886,40788,730,35254,245,77675,928,72778,752,211111,105,06569,365,64437,727,28272,734,463102,341,59041,407,61080,553,05077,789,732
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100,946,525
110,175,857
118,465,916
438,172,860
446,256,244
458,381,048
462,405,994
462,405,994458,381,048446,256,244438,172,860118,465,916110,175,857100,946,5250000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,734,543
44,718,792
50,758,556
364,693,620
362,170,180
397,521,286
431,899,687
431,899,687397,521,286362,170,180364,693,62050,758,55644,718,79244,734,5430000000000000000
       Other Liabilities 
0
1,565,097
3,315,204
5,355,204
21,382,920
23,255,350
27,109,513
31,577,121
34,640,587
36,652,537
41,542,124
45,864,393
49,393,682
32,741,329
40,186,169
44,537,244
56,211,982
65,457,066
67,707,360
73,479,240
84,086,064
60,859,762
0
060,859,76284,086,06473,479,24067,707,36065,457,06656,211,98244,537,24440,186,16932,741,32949,393,68245,864,39341,542,12436,652,53734,640,58731,577,12127,109,51323,255,35021,382,9205,355,2043,315,2041,565,0970
> Total Stockholder Equity
292,565,201
510,844,463
390,435,501
260,865,170
255,664,672
265,245,147
280,485,822
291,562,629
296,594,528
298,720,166
311,266,810
609,192,393
650,100,577
590,792,019
591,958,093
592,705,025
575,753,992
526,408,631
496,646,167
504,933,640
430,321,799
508,295,782
86,359,127
86,359,127508,295,782430,321,799504,933,640496,646,167526,408,631575,753,992592,705,025591,958,093590,792,019650,100,577609,192,393311,266,810298,720,166296,594,528291,562,629280,485,822265,245,147255,664,672260,865,170390,435,501510,844,463292,565,201
   Common Stock
160,000,000
309,687,500
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750
309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,926,750309,687,500160,000,000
   Retained Earnings 
105,374,179
117,624,723
0
0
0
0
0
0
0
0
0
20,820,856
61,729,041
2,420,483
3,586,556
207,627,334
184,656,595
135,311,235
-85,989,562
-78,028,599
-148,980,464
-186,561,104
-615,024,058
-615,024,058-186,561,104-148,980,464-78,028,599-85,989,562135,311,235184,656,595207,627,3343,586,5562,420,48361,729,04120,820,856000000000117,624,723105,374,179
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
81,120,061
81,120,061
81,120,061
81,120,061
81,120,061
81,120,061
81,120,061
81,120,06181,120,06181,120,06181,120,06181,120,06181,120,06181,120,0610000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,585
50,585
50,585
191,588,918
191,915,428
188,255,452
303,810,075
106,992,070
106,992,070303,810,075188,255,452191,915,428191,588,91850,58550,58550,585000000000000000



Balance Sheet

Currency in IDR. All numbers in thousands.




Cash Flow

Currency in IDR. All numbers in thousands.




Income Statement

Currency in IDR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue684,912,941
Cost of Revenue-861,126,530
Gross Profit-176,213,589-176,213,589
 
Operating Income (+$)
Gross Profit-176,213,589
Operating Expense-1,174,745,616
Operating Income-489,832,675-1,350,959,205
 
Operating Expense (+$)
Research Development-
Selling General Administrative70,802,267
Selling And Marketing Expenses-
Operating Expense1,174,745,61670,802,267
 
Net Interest Income (+$)
Interest Income5,419,765
Interest Expense-48,019,296
Other Finance Cost-0
Net Interest Income-42,599,531
 
Pretax Income (+$)
Operating Income-489,832,675
Net Interest Income-42,599,531
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-540,913,430-489,832,675
EBIT - interestExpense = -48,019,296
-437,052,654
-389,033,358
Interest Expense48,019,296
Earnings Before Interest and Taxes (EBIT)--492,894,134
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-540,913,430
Tax Provision--103,837,880
Net Income From Continuing Ops-437,075,550-437,075,550
Net Income-437,052,654
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-42,599,531
 

Technical Analysis of Indofarma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Indofarma. The general trend of Indofarma is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Indofarma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Indofarma Tbk.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 380.00 < 406.00 < 430.00.

The bearish price targets are: .

Tweet this
Indofarma Tbk Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Indofarma Tbk. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Indofarma Tbk Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Indofarma Tbk. The current macd is -67.08567085.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Indofarma price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Indofarma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Indofarma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Indofarma Tbk Daily Moving Average Convergence/Divergence (MACD) ChartIndofarma Tbk Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Indofarma Tbk. The current adx is 51.03.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Indofarma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Indofarma Tbk Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Indofarma Tbk. The current sar is 190.39.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Indofarma Tbk Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Indofarma Tbk. The current rsi is 9.2540882. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Indofarma Tbk Daily Relative Strength Index (RSI) ChartIndofarma Tbk Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Indofarma Tbk. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Indofarma price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Indofarma Tbk Daily Stochastic Oscillator ChartIndofarma Tbk Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Indofarma Tbk. The current cci is -109.1422367.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Indofarma Tbk Daily Commodity Channel Index (CCI) ChartIndofarma Tbk Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Indofarma Tbk. The current cmo is -89.09754042.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Indofarma Tbk Daily Chande Momentum Oscillator (CMO) ChartIndofarma Tbk Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Indofarma Tbk. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Indofarma Tbk Daily Williams %R ChartIndofarma Tbk Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Indofarma Tbk.

Indofarma Tbk Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Indofarma Tbk. The current atr is 14.64.

Indofarma Tbk Daily Average True Range (ATR) ChartIndofarma Tbk Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Indofarma Tbk. The current obv is 521,200.

Indofarma Tbk Daily On-Balance Volume (OBV) ChartIndofarma Tbk Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Indofarma Tbk. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Indofarma Tbk Daily Money Flow Index (MFI) ChartIndofarma Tbk Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Indofarma Tbk.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Indofarma Tbk Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Indofarma Tbk based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than509.254
Ma 20Greater thanMa 50255.450
Ma 50Greater thanMa 100343.860
Ma 100Greater thanMa 200431.060
OpenGreater thanClose132.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Indofarma with someone you think should read this too:
  • Are you bullish or bearish on Indofarma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Indofarma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Indofarma Tbk

I send you an email if I find something interesting about Indofarma Tbk.


Comments

How you think about this?

Leave a comment

Stay informed about Indofarma Tbk.

Receive notifications about Indofarma Tbk in your mailbox!